Novastan data

Results from a Phase II dose-ranging trial in 13 patients undergoing coronary procedures showed adequate anticoagulation in all patients, and no significant adverse events.

Primary end points were adequate anticoagulation and angiographic success of the intervention. Doses weren't disclosed. Patients in the study had been unable to undergo these procedures because of heparin-induced thrombocytopenia or thrombosis syndrome. ...